Vibrant America



Thyroid autoantibodies AS early prediction MARKERS IN thyroid diseaseVibrant America, LLCThyroid DISEASEThyroid disease has been considered one of the most common autoimmune diseases since its two major clinical diseases, hypothyroidism (often caused by Hashimoto’s disease) and hyperthyroidism (mainly by Grave’s disease) are caused by auto antibodies. ADDIN EN.CITE <EndNote><Cite><Author>Ladenson</Author><Year>2000</Year><RecNum>108</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1524876135">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ladenson, P. W.</author><author>Singer, P. A.</author><author>Ain, K. B.</author><author>Bagchi, N.</author><author>Bigos, S. T.</author><author>Levy, E. G.</author><author>Smith, S. A.</author><author>Daniels, G. H.</author><author>Cohen, H. D.</author></authors></contributors><auth-address>The Johns Hopkins University School of Medicine, Baltimore, MD 21287-0003, USA. ladenson@jhu.edu</auth-address><titles><title>American Thyroid Association guidelines for detection of thyroid dysfunction</title><secondary-title>Arch Intern Med</secondary-title></titles><periodical><full-title>Arch Intern Med</full-title></periodical><pages>1573-5</pages><volume>160</volume><number>11</number><keywords><keyword>Adult</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Medical History Taking/standards</keyword><keyword>Thyroid Diseases/*diagnosis</keyword><keyword>Thyroid Function Tests/standards</keyword><keyword>United States</keyword></keywords><dates><year>2000</year><pub-dates><date>Jun 12</date></pub-dates></dates><isbn>0003-9926 (Print)&#xD;0003-9926 (Linking)</isbn><accession-num>10847249</accession-num><urls><related-urls><url> Thyroid disease is mainly associated with decreased quality of life, Grave’s ophthalmopathy and dermopathy, osteoporosis, cardiovascular diseases and inherent risks in pregnant women and neonates.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NZWRpY2k8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxS

ZWNOdW0+MTUwNTwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQi

PjItMzwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjE1MDU8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSIweGZ3eGUwdGphNXdlMmVh

Mjl0eDJmZmcwOWVlOXdmZjJ0NXQiIHRpbWVzdGFtcD0iMTUyNTExMjc0NyI+MTUwNTwva2V5Pjwv

Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw

ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWVkaWNpLCBNLjwvYXV0aG9yPjxhdXRo

b3I+S29yZXZhYXIsIFQuIEkuPC9hdXRob3I+PGF1dGhvcj5TY2hhbGVrYW1wLVRpbW1lcm1hbnMs

IFMuPC9hdXRob3I+PGF1dGhvcj5HYWlsbGFyZCwgUi48L2F1dGhvcj48YXV0aG9yPmRlIFJpamtl

LCBZLiBCLjwvYXV0aG9yPjxhdXRob3I+Vmlzc2VyLCBXLiBFLjwvYXV0aG9yPjxhdXRob3I+Vmlz

c2VyLCBXLjwvYXV0aG9yPjxhdXRob3I+ZGUgTXVpbmNrIEtlaXplci1TY2hyYW1hLCBTLiBNLjwv

YXV0aG9yPjxhdXRob3I+SG9mbWFuLCBBLjwvYXV0aG9yPjxhdXRob3I+SG9vaWprYWFzLCBILjwv

YXV0aG9yPjxhdXRob3I+Qm9uZ2Vycy1TY2hva2tpbmcsIEouIEouPC9hdXRob3I+PGF1dGhvcj5U

aWVtZWllciwgSC48L2F1dGhvcj48YXV0aG9yPkphZGRvZSwgVi4gVy48L2F1dGhvcj48YXV0aG9y

PlZpc3NlciwgVC4gSi48L2F1dGhvcj48YXV0aG9yPlBlZXRlcnMsIFIuIFAuPC9hdXRob3I+PGF1

dGhvcj5TdGVlZ2VycywgRS4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1

dGgtYWRkcmVzcz5UaGUgR2VuZXJhdGlvbiBSIFN0dWR5IEdyb3VwIChNLk0uLCBULkkuTS5LLiwg

Uy5TLi1ULiwgUi5HLiwgVi5XLlYuSi4pIGFuZCBEZXBhcnRtZW50cyBvZiBJbnRlcm5hbCBNZWRp

Y2luZSAoTS5NLiwgVC5JLk0uSy4sIFkuQi5kLlIuLCBXLkUuVi4sIFQuSi5WLiwgUi5QLlAuKSwg

RXBpZGVtaW9sb2d5IChSLkcuLCBBLkguLCBWLlcuVi5KLiksIGFuZCBJbW11bm9sb2d5IChILkgu

KSwgRXJhc211cyBNZWRpY2FsIENlbnRlciwgMzAxNSBHRSBSb3R0ZXJkYW0sIFRoZSBOZXRoZXJs

YW5kczsgYW5kIERlcGFydG1lbnRzIG9mIE9ic3RldHJpY3MgYW5kIEd5bmVjb2xvZ3kgKFMuUy4t

VC4sIFcuVi4sIEUuQS5QLlMuKSwgUGVkaWF0cmljcyAoUi5HLiwgUy5NLlAuRi5kLk0uSy4tUy4s

IEouSi5CLi1TLiwgSC5ULiwgVi5XLlYuSi4pLCBDbGluaWNhbCBDaGVtaXN0cnkgKFkuQi5kLlIu

KSwgYW5kIENoaWxkIGFuZCBBZG9sZXNjZW50IFBzeWNoaWF0cnkgKEguVC4pLCBFcmFzbXVzIE1l

ZGljYWwgQ2VudGVyLCBTb3BoaWEgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsLCAzMDAwIERSIFJv

dHRlcmRhbSwgVGhlIE5ldGhlcmxhbmRzLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk1h

dGVybmFsIGVhcmx5LXByZWduYW5jeSB0aHlyb2lkIGZ1bmN0aW9uIGlzIGFzc29jaWF0ZWQgd2l0

aCBzdWJzZXF1ZW50IGh5cGVydGVuc2l2ZSBkaXNvcmRlcnMgb2YgcHJlZ25hbmN5OiB0aGUgZ2Vu

ZXJhdGlvbiBSIHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogQ2xpbiBFbmRvY3Jpbm9s

IE1ldGFiPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SiBDbGluIEVuZG9jcmlub2wgTWV0YWI8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz5F

MjU5MS04PC9wYWdlcz48dm9sdW1lPjk5PC92b2x1bWU+PG51bWJlcj4xMjwvbnVtYmVyPjxrZXl3

b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5CbG9vZCBQcmVzc3VyZS9waHlz

aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNvaG9ydCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3Jk

PkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlwZXJ0

ZW5zaW9uLCBQcmVnbmFuY3ktSW5kdWNlZC8qcGh5c2lvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3

b3JkPklvZGluZS9ibG9vZC91cmluZTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdv

cmQ+PGtleXdvcmQ+UHJlZ25hbmN5IFRyaW1lc3RlciwgRmlyc3Q8L2tleXdvcmQ+PGtleXdvcmQ+

UmlzayBBc3Nlc3NtZW50PC9rZXl3b3JkPjxrZXl3b3JkPlRoeXJvaWQgRGlzZWFzZXMvKnBoeXNp

b3BhdGhvbG9neTwva2V5d29yZD48a2V5d29yZD5UaHlyb2lkIEZ1bmN0aW9uIFRlc3RzPC9rZXl3

b3JkPjxrZXl3b3JkPlRoeXJvaWQgR2xhbmQvKnBoeXNpb3BhdGhvbG9neTwva2V5d29yZD48a2V5

d29yZD5UaHlyb2lkaXRpcywgQXV0b2ltbXVuZS9jb21wbGljYXRpb25zPC9rZXl3b3JkPjwva2V5

d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5EZWM8L2RhdGU+

PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xOTQ1LTcxOTcgKEVsZWN0cm9uaWMpJiN4RDswMDIx

LTk3MlggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1MTU3NTQwPC9hY2Nlc3Npb24t

bnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292

L3B1Ym1lZC8yNTE1NzU0MDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+MTAuMTIxMC9qYy4yMDE0LTE1MDU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVt

PjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlRyaWdnaWFuaTwvQXV0aG9yPjxZZWFyPjIw

MTM8L1llYXI+PFJlY051bT4xMDgzPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xMDgzPC9y

ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMHhmd3hlMHRqYTV3

ZTJlYTI5dHgyZmZnMDllZTl3ZmYydDV0IiB0aW1lc3RhbXA9IjE1MjUxMTEzMDIiPjEwODM8L2tl

eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlRyaWdnaWFuaSwgVi48L2F1dGhv

cj48YXV0aG9yPklhY292aWVsbG8sIE0uPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz

PjxhdXRoLWFkZHJlc3M+RW5kb2NyaW5vbG9neSBhbmQgTWV0YWJvbGljIERpc2Vhc2VzLCBJbnRl

cmRpc2NpcGxpbmFyeSBEZXBhcnRtZW50IG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJhcmkg

JnF1b3Q7QWxkbyBNb3JvJnF1b3Q7IFNjaG9vbCBvZiBNZWRpY2luZSwgUG9saWNsaW5pY28sIEJh

cmksIEl0YWx5LiB2LnRyaWdnaWFuaUBlbmRvLnVuaWJhLml0PC9hdXRoLWFkZHJlc3M+PHRpdGxl

cz48dGl0bGU+VGh5cm9pZCBkaXNvcmRlcnMgaW4gY2hyb25pYyBoZWFydCBmYWlsdXJlOiBmcm9t

IHByb2dub3N0aWMgc2V0LXVwIHRvIHRoZXJhcGV1dGljIG1hbmFnZW1lbnQ8L3RpdGxlPjxzZWNv

bmRhcnktdGl0bGU+RW5kb2NyIE1ldGFiIEltbXVuZSBEaXNvcmQgRHJ1ZyBUYXJnZXRzPC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+RW5kb2NyIE1ldGFi

IEltbXVuZSBEaXNvcmQgRHJ1ZyBUYXJnZXRzPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn

ZXM+MjItMzc8L3BhZ2VzPjx2b2x1bWU+MTM8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5

d29yZHM+PGtleXdvcmQ+Q2hyb25pYyBEaXNlYXNlPC9rZXl3b3JkPjxrZXl3b3JkPkhlYXJ0IEZh

aWx1cmUvZGlhZ25vc2lzLypldGlvbG9neS8qdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5IdW1h

bnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3JkPjxrZXl3b3JkPlRoeXJvaWQg

RGlzZWFzZXMvKmNvbXBsaWNhdGlvbnMvZGlhZ25vc2lzLyp0aGVyYXB5PC9rZXl3b3JkPjxrZXl3

b3JkPlRoeXJvaWQgSG9ybW9uZXMvZGVmaWNpZW5jeTwva2V5d29yZD48a2V5d29yZD5UcmVhdG1l

bnQgT3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFyPjxw

dWItZGF0ZXM+PGRhdGU+TWFyPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MjIxMi0z

ODczIChFbGVjdHJvbmljKSYjeEQ7MTg3MS01MzAzIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9u

LW51bT4yMzM2OTEzNTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0

cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjMzNjkxMzU8L3VybD48L3JlbGF0ZWQt

dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NZWRpY2k8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxS

ZWNOdW0+MTUwNTwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQi

PjItMzwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjE1MDU8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSIweGZ3eGUwdGphNXdlMmVh

Mjl0eDJmZmcwOWVlOXdmZjJ0NXQiIHRpbWVzdGFtcD0iMTUyNTExMjc0NyI+MTUwNTwva2V5Pjwv

Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw

ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWVkaWNpLCBNLjwvYXV0aG9yPjxhdXRo

b3I+S29yZXZhYXIsIFQuIEkuPC9hdXRob3I+PGF1dGhvcj5TY2hhbGVrYW1wLVRpbW1lcm1hbnMs

IFMuPC9hdXRob3I+PGF1dGhvcj5HYWlsbGFyZCwgUi48L2F1dGhvcj48YXV0aG9yPmRlIFJpamtl

LCBZLiBCLjwvYXV0aG9yPjxhdXRob3I+Vmlzc2VyLCBXLiBFLjwvYXV0aG9yPjxhdXRob3I+Vmlz

c2VyLCBXLjwvYXV0aG9yPjxhdXRob3I+ZGUgTXVpbmNrIEtlaXplci1TY2hyYW1hLCBTLiBNLjwv

YXV0aG9yPjxhdXRob3I+SG9mbWFuLCBBLjwvYXV0aG9yPjxhdXRob3I+SG9vaWprYWFzLCBILjwv

YXV0aG9yPjxhdXRob3I+Qm9uZ2Vycy1TY2hva2tpbmcsIEouIEouPC9hdXRob3I+PGF1dGhvcj5U

aWVtZWllciwgSC48L2F1dGhvcj48YXV0aG9yPkphZGRvZSwgVi4gVy48L2F1dGhvcj48YXV0aG9y

PlZpc3NlciwgVC4gSi48L2F1dGhvcj48YXV0aG9yPlBlZXRlcnMsIFIuIFAuPC9hdXRob3I+PGF1

dGhvcj5TdGVlZ2VycywgRS4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1

dGgtYWRkcmVzcz5UaGUgR2VuZXJhdGlvbiBSIFN0dWR5IEdyb3VwIChNLk0uLCBULkkuTS5LLiwg

Uy5TLi1ULiwgUi5HLiwgVi5XLlYuSi4pIGFuZCBEZXBhcnRtZW50cyBvZiBJbnRlcm5hbCBNZWRp

Y2luZSAoTS5NLiwgVC5JLk0uSy4sIFkuQi5kLlIuLCBXLkUuVi4sIFQuSi5WLiwgUi5QLlAuKSwg

RXBpZGVtaW9sb2d5IChSLkcuLCBBLkguLCBWLlcuVi5KLiksIGFuZCBJbW11bm9sb2d5IChILkgu

KSwgRXJhc211cyBNZWRpY2FsIENlbnRlciwgMzAxNSBHRSBSb3R0ZXJkYW0sIFRoZSBOZXRoZXJs

YW5kczsgYW5kIERlcGFydG1lbnRzIG9mIE9ic3RldHJpY3MgYW5kIEd5bmVjb2xvZ3kgKFMuUy4t

VC4sIFcuVi4sIEUuQS5QLlMuKSwgUGVkaWF0cmljcyAoUi5HLiwgUy5NLlAuRi5kLk0uSy4tUy4s

IEouSi5CLi1TLiwgSC5ULiwgVi5XLlYuSi4pLCBDbGluaWNhbCBDaGVtaXN0cnkgKFkuQi5kLlIu

KSwgYW5kIENoaWxkIGFuZCBBZG9sZXNjZW50IFBzeWNoaWF0cnkgKEguVC4pLCBFcmFzbXVzIE1l

ZGljYWwgQ2VudGVyLCBTb3BoaWEgQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsLCAzMDAwIERSIFJv

dHRlcmRhbSwgVGhlIE5ldGhlcmxhbmRzLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk1h

dGVybmFsIGVhcmx5LXByZWduYW5jeSB0aHlyb2lkIGZ1bmN0aW9uIGlzIGFzc29jaWF0ZWQgd2l0

aCBzdWJzZXF1ZW50IGh5cGVydGVuc2l2ZSBkaXNvcmRlcnMgb2YgcHJlZ25hbmN5OiB0aGUgZ2Vu

ZXJhdGlvbiBSIHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogQ2xpbiBFbmRvY3Jpbm9s

IE1ldGFiPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SiBDbGluIEVuZG9jcmlub2wgTWV0YWI8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz5F

MjU5MS04PC9wYWdlcz48dm9sdW1lPjk5PC92b2x1bWU+PG51bWJlcj4xMjwvbnVtYmVyPjxrZXl3

b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5CbG9vZCBQcmVzc3VyZS9waHlz

aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNvaG9ydCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3Jk

PkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlwZXJ0

ZW5zaW9uLCBQcmVnbmFuY3ktSW5kdWNlZC8qcGh5c2lvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3

b3JkPklvZGluZS9ibG9vZC91cmluZTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdv

cmQ+PGtleXdvcmQ+UHJlZ25hbmN5IFRyaW1lc3RlciwgRmlyc3Q8L2tleXdvcmQ+PGtleXdvcmQ+

UmlzayBBc3Nlc3NtZW50PC9rZXl3b3JkPjxrZXl3b3JkPlRoeXJvaWQgRGlzZWFzZXMvKnBoeXNp

b3BhdGhvbG9neTwva2V5d29yZD48a2V5d29yZD5UaHlyb2lkIEZ1bmN0aW9uIFRlc3RzPC9rZXl3

b3JkPjxrZXl3b3JkPlRoeXJvaWQgR2xhbmQvKnBoeXNpb3BhdGhvbG9neTwva2V5d29yZD48a2V5

d29yZD5UaHlyb2lkaXRpcywgQXV0b2ltbXVuZS9jb21wbGljYXRpb25zPC9rZXl3b3JkPjwva2V5

d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5EZWM8L2RhdGU+

PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xOTQ1LTcxOTcgKEVsZWN0cm9uaWMpJiN4RDswMDIx

LTk3MlggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1MTU3NTQwPC9hY2Nlc3Npb24t

bnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292

L3B1Ym1lZC8yNTE1NzU0MDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+MTAuMTIxMC9qYy4yMDE0LTE1MDU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVt

PjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlRyaWdnaWFuaTwvQXV0aG9yPjxZZWFyPjIw

MTM8L1llYXI+PFJlY051bT4xMDgzPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xMDgzPC9y

ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMHhmd3hlMHRqYTV3

ZTJlYTI5dHgyZmZnMDllZTl3ZmYydDV0IiB0aW1lc3RhbXA9IjE1MjUxMTEzMDIiPjEwODM8L2tl

eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlRyaWdnaWFuaSwgVi48L2F1dGhv

cj48YXV0aG9yPklhY292aWVsbG8sIE0uPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz

PjxhdXRoLWFkZHJlc3M+RW5kb2NyaW5vbG9neSBhbmQgTWV0YWJvbGljIERpc2Vhc2VzLCBJbnRl

cmRpc2NpcGxpbmFyeSBEZXBhcnRtZW50IG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJhcmkg

JnF1b3Q7QWxkbyBNb3JvJnF1b3Q7IFNjaG9vbCBvZiBNZWRpY2luZSwgUG9saWNsaW5pY28sIEJh

cmksIEl0YWx5LiB2LnRyaWdnaWFuaUBlbmRvLnVuaWJhLml0PC9hdXRoLWFkZHJlc3M+PHRpdGxl

cz48dGl0bGU+VGh5cm9pZCBkaXNvcmRlcnMgaW4gY2hyb25pYyBoZWFydCBmYWlsdXJlOiBmcm9t

IHByb2dub3N0aWMgc2V0LXVwIHRvIHRoZXJhcGV1dGljIG1hbmFnZW1lbnQ8L3RpdGxlPjxzZWNv

bmRhcnktdGl0bGU+RW5kb2NyIE1ldGFiIEltbXVuZSBEaXNvcmQgRHJ1ZyBUYXJnZXRzPC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+RW5kb2NyIE1ldGFi

IEltbXVuZSBEaXNvcmQgRHJ1ZyBUYXJnZXRzPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn

ZXM+MjItMzc8L3BhZ2VzPjx2b2x1bWU+MTM8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5

d29yZHM+PGtleXdvcmQ+Q2hyb25pYyBEaXNlYXNlPC9rZXl3b3JkPjxrZXl3b3JkPkhlYXJ0IEZh

aWx1cmUvZGlhZ25vc2lzLypldGlvbG9neS8qdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5IdW1h

bnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3JkPjxrZXl3b3JkPlRoeXJvaWQg

RGlzZWFzZXMvKmNvbXBsaWNhdGlvbnMvZGlhZ25vc2lzLyp0aGVyYXB5PC9rZXl3b3JkPjxrZXl3

b3JkPlRoeXJvaWQgSG9ybW9uZXMvZGVmaWNpZW5jeTwva2V5d29yZD48a2V5d29yZD5UcmVhdG1l

bnQgT3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFyPjxw

dWItZGF0ZXM+PGRhdGU+TWFyPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MjIxMi0z

ODczIChFbGVjdHJvbmljKSYjeEQ7MTg3MS01MzAzIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9u

LW51bT4yMzM2OTEzNTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0

cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjMzNjkxMzU8L3VybD48L3JlbGF0ZWQt

dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 2-3 Rarely, it can be life threatening causing myxedema coma or thyroid storm. ADDIN EN.CITE <EndNote><Cite><Author>Hampton</Author><Year>2013</Year><RecNum>2956</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>2956</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1525113166">2956</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hampton, J.</author></authors></contributors><auth-address>Inpatient Diabetes Management, University of Minnesota Physicians, 420 Delaware Street SE, Minneapolis, MN 55455, USA. jhampton10@umphysicians.umn.edu</auth-address><titles><title>Thyroid gland disorder emergencies: thyroid storm and myxedema coma</title><secondary-title>AACN Adv Crit Care</secondary-title></titles><periodical><full-title>AACN Adv Crit Care</full-title></periodical><pages>325-32</pages><volume>24</volume><number>3</number><keywords><keyword>Adult</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Myxedema/*diagnosis/physiopathology/therapy</keyword><keyword>Thyroid Crisis/*diagnosis/physiopathology/therapy</keyword><keyword>United States</keyword><keyword>Young Adult</keyword></keywords><dates><year>2013</year><pub-dates><date>Jul-Sep</date></pub-dates></dates><isbn>1559-7776 (Electronic)&#xD;1559-7768 (Linking)</isbn><accession-num>23880755</accession-num><urls><related-urls><url> A set of hormones and autoantibodies are associated with thyroid disease such as thyroid-stimulating hormone (TSH), thyroxine (T4), triiodothyronine (T3), reverse T3, anti-TPO, anti- Tg etc., but TSH and FT4 are considered the cornerstone markers when determining thyroid disease. ADDIN EN.CITE <EndNote><Cite><Author>Stockigt</Author><Year>2003</Year><RecNum>2960</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>2960</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1525113624">2960</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stockigt, J.</author></authors></contributors><auth-address>Department of Endocrinology and Diabetes, Monash University Department of Medicine, Alfred Hospital, Prahran, VIC, Australia. jrs@.au</auth-address><titles><title>Assessment of thyroid function: towards an integrated laboratory--clinical approach</title><secondary-title>Clin Biochem Rev</secondary-title></titles><periodical><full-title>Clin Biochem Rev</full-title></periodical><pages>109-22</pages><volume>24</volume><number>4</number><dates><year>2003</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>0159-8090 (Print)&#xD;0159-8090 (Linking)</isbn><accession-num>18568049</accession-num><urls><related-urls><url> Thyroid disease is not one particular disorder but a spectrum of diseases with both asymptomatic and symptomatic disease stages. The disease stage is often determined by evaluating the symptoms and serum levels of thyroid hormones, specially TSH and Free T4(FT4), since FT4 gives the unbound active amount of T4 in blood rather than the total T4 including inactive protein-bound hormone. This spectrum of disease can be ranged starting from asymptomatic subclinical hypothyroidism (high TSH, FT4 in-range) and sub clinical hyperthyroidism (low TSH, FT4 in-range) to overt hypothyroidism (low TSH and high FT4) and overt hyperthyroidism (high TSH and low FT4) which may or may not have symptoms. The end of the spectrum is the symptomatic thyroid disease which is associated with both abnormalities in serum levels of TSH and FT4 and physical symptoms. ADDIN EN.CITE <EndNote><Cite><Author>LeFevre</Author><Year>2015</Year><RecNum>109</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1524876248">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>LeFevre, M. L.</author><author>U. S. Preventive Services Task Force</author></authors></contributors><titles><title>Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement</title><secondary-title>Ann Intern Med</secondary-title></titles><periodical><full-title>Ann Intern Med</full-title></periodical><pages>641-50</pages><volume>162</volume><number>9</number><keywords><keyword>Adult</keyword><keyword>Asymptomatic Diseases</keyword><keyword>Biomedical Research</keyword><keyword>Early Diagnosis</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>*Mass Screening</keyword><keyword>Risk Assessment</keyword><keyword>Thyroid Diseases/*diagnosis/*therapy</keyword><keyword>Thyroid Function Tests</keyword><keyword>Thyroid Hormones/blood</keyword><keyword>United States</keyword></keywords><dates><year>2015</year><pub-dates><date>May 5</date></pub-dates></dates><isbn>1539-3704 (Electronic)&#xD;0003-4819 (Linking)</isbn><accession-num>25798805</accession-num><urls><related-urls><url> center32067500Figure 1. Traditional Patient Assessment Stratification for Thyroid Dysfunction ADDIN EN.CITE <EndNote><Cite><Author>Siemens Medical Solutions USA</Author><RecNum>3379</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>3379</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1526424238">3379</key></foreign-keys><ref-type name="Online Multimedia">48</ref-type><contributors><authors><author>Siemens Medical Solutions USA, Inc</author></authors></contributors><titles></titles><dates></dates><urls><related-urls><url> antibodies as early prediction markers in thyroid diseaseEven though thyroid disease is not life threatening, early detection and treatment of thyroid disease would prevent long-term morbidity and mortality from cancer, osteoporosis, cardiovascular diseases and specially reduce the risks of miscarriages in asymptomatic patients if identified early and treated appropriately. Hutfless et al showed that thyroid autoantibodies, mainly anti-thyroperoxidase (TPO), anti-thyroglobulin (Tg) are present up to 7 years before clinical diagnosis in Graves’s and Hashimoto disease patients. ADDIN EN.CITE <EndNote><Cite><Author>Hutfless</Author><Year>2011</Year><RecNum>497</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1525109466">497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hutfless, S.</author><author>Matos, P.</author><author>Talor, M. V.</author><author>Caturegli, P.</author><author>Rose, N. R.</author></authors></contributors><titles><title>Significance of Prediagnostic Thyroid Antibodies in Women with Autoimmune Thyroid Disease</title><secondary-title>J Clin Endocrinol Metab</secondary-title></titles><periodical><full-title>J Clin Endocrinol Metab</full-title></periodical><pages>E1466–E1471</pages><volume>96</volume><number>9</number><dates><year>2011</year></dates><urls></urls><electronic-resource-num>10.1210/jc.2011-0228</electronic-resource-num></record></Cite></EndNote>8 Hence, measuring anti-TPO and anti-Tg as a first-tier screening test in conjunction with TSH and FT4 would clearly serve as a disease predictive as well as confirmatory markers, thus be helpful for close monitoring, early treatments and supplements to prevent long term morbidity. Our STUDY: Early occurance of thyroid autoantibodies, anti-tpo and anti-tgMethodThe eligible study population comprised of subjects who were addressed to Vibrant America Clinical Laboratory between May 2016 to April 2018 for minimum four thyroid disease markers (Free T4 hormone (FT4), TSH, anti-TPO, anti-Tg). Anti-TPO and anti-Tg auto antibodies as early markersAnti TPO, anti Tg TSH and FT4 were evaluated in Group A1 (anti-TPO was positive at the first visit and consistent but TSH and FT4 were in range for at least the first visit) and group A2 (anti-Tg was positive at the first visit and consistent but TSH and FT4 were in range for at least the first visit) subjects. right10160ABABFigure 1. Conversion of group A1(A) and group A2(B) subjects into different thyroid disease sub categories for over two years of follow up testing for thyroid disease hormones.In group A1, 151 (35%) subjects who had anti-TPO autoantibodies have developed into an atypical TSH or FT4 condition, where approximately 71 (47%) of them converted to sub-clinical or overt hypothyroid or hyperthyroid condition, during the 23 months. Similarly, in group A2, 118 (35%) had anti-Tg prior the onset of atypical TSH or FT4, where approximately 52 (44%) of them converted to sub-clinical or overt hypothyroid or hyperthyroid condition, during the 23 months. The remaining 65% subjects who had TSH and FT4 in range in both group A1 and group A2 may have the potential to develop into asymptomatic condition and later symptomatic thyroid disease. This hypothesis is based on a study that Hutfless et al. showed on the preexistence of anti-TPO and anti-Tg autoantibodies 7 years prior to the concise diagnosis of Hashimoto’s (66% and 57% for anti TPO and anti Tg respectively) and Graves’ disease (57% and 47% for anti- TPO and anti-Tg respectively) for 174 patients. ADDIN EN.CITE <EndNote><Cite><Author>Hutfless</Author><Year>2011</Year><RecNum>497</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1525109466">497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hutfless, S.</author><author>Matos, P.</author><author>Talor, M. V.</author><author>Caturegli, P.</author><author>Rose, N. R.</author></authors></contributors><titles><title>Significance of Prediagnostic Thyroid Antibodies in Women with Autoimmune Thyroid Disease</title><secondary-title>J Clin Endocrinol Metab</secondary-title></titles><periodical><full-title>J Clin Endocrinol Metab</full-title></periodical><pages>E1466–E1471</pages><volume>96</volume><number>9</number><dates><year>2011</year></dates><urls></urls><electronic-resource-num>10.1210/jc.2011-0228</electronic-resource-num></record></Cite></EndNote>8Prevalence of Anti-TPO and anti-Tg antibodies01755775ABABGroup B1 (TSH and FT4 was in range for the first visit and subsequently converted to subclinical/ overt hypothyroidism) and group B2 (TSH and FT4 was in range for the first visit and subsequently converted to subclinical/ overt hyperthyroidism) were evaluated for the early occurrence of anti-TPO and anti-Tg autoantibodies. A total of 30 (71%) and 26 (62%) subjects of group B1 had anti-TPO and anti-Tg prior to any out-of-range TSH or FT4 level in an average time of 263(±31) days and 218(±94) days respectively. Similarly, 41 (72%) subjects of group B2 had anti-TPO prior to developing into out-of-range TSH and FT4 levels in an average of 292(±163) but the occurrence of anti-Tg was Figure 4. Prevalence of anti-TPO and anti-Tg in group B1(A) and group B2(B) with subjects who were converted to subclinical/overt hypothyroidism not significant. These results prove that they are useful not only as early predictive markers but also as secondary confirmatory markers in borderline TSH subjects with sub clinical hypothyroidism/ hyperthyroid disease. Moreover, the results were consistent with Huftless et al where they confirmed that anti-TPO was present in 66% Hashimotos patients and 57% Grave’s diseases patients before 7 years of clinical diagnosis. ADDIN EN.CITE <EndNote><Cite><Author>Hutfless</Author><Year>2011</Year><RecNum>497</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1525109466">497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hutfless, S.</author><author>Matos, P.</author><author>Talor, M. V.</author><author>Caturegli, P.</author><author>Rose, N. R.</author></authors></contributors><titles><title>Significance of Prediagnostic Thyroid Antibodies in Women with Autoimmune Thyroid Disease</title><secondary-title>J Clin Endocrinol Metab</secondary-title></titles><periodical><full-title>J Clin Endocrinol Metab</full-title></periodical><pages>E1466–E1471</pages><volume>96</volume><number>9</number><dates><year>2011</year></dates><urls></urls><electronic-resource-num>10.1210/jc.2011-0228</electronic-resource-num></record></Cite></EndNote>8 They also showed that anti-Tg was not as prominent as anti-TPO with a low percentage of 57% in Hashimoto’s patients and 47% in Graves’ disease patients in their study. ADDIN EN.CITE <EndNote><Cite><Author>Hutfless</Author><Year>2011</Year><RecNum>497</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="0xfwxe0tja5we2ea29tx2ffg09ee9wff2t5t" timestamp="1525109466">497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hutfless, S.</author><author>Matos, P.</author><author>Talor, M. V.</author><author>Caturegli, P.</author><author>Rose, N. R.</author></authors></contributors><titles><title>Significance of Prediagnostic Thyroid Antibodies in Women with Autoimmune Thyroid Disease</title><secondary-title>J Clin Endocrinol Metab</secondary-title></titles><periodical><full-title>J Clin Endocrinol Metab</full-title></periodical><pages>E1466–E1471</pages><volume>96</volume><number>9</number><dates><year>2011</year></dates><urls></urls><electronic-resource-num>10.1210/jc.2011-0228</electronic-resource-num></record></Cite></EndNote>8 Similarly, our data showed anti-Tg had seen early in only 61% of subclinical/overt hypothyroid patients but showed a non-significant difference of 45% in patients who developed into sub-clinical/overt hyperthyroidism.Finally, we evaluated each antibody’s ability to perform as a standalone test in group B1 and B2. These subjects were compared, first with the subjects that were only assessed for early incidence of anti TPO and then with the subjects that were only assessed for early incidence of anti Tg separately in both sub clinical/overt hypothyroidism and hyperthyroidism. Of the 42 subjects in group B1 who left2038985Figure 6. Comparison of the prevalence of anti TPO, anti Tg and combined anti TPO or anti Tg in subjects converted to sub clinical/overt hypothyroidism (group B1) and hyperthyroidism (group B2). 020000Figure 6. Comparison of the prevalence of anti TPO, anti Tg and combined anti TPO or anti Tg in subjects converted to sub clinical/overt hypothyroidism (group B1) and hyperthyroidism (group B2). 289560-317500had converted to sub clinical/overt hypothyroidism, 36 (85%) had either anti TPO or anti Tg early than the onset of sub clinical/overt hypothyroidism compared to 30 subjects who had early incidence of anti-TPO and 26 subjects who had early incidence of anti Tg alone. Within the 57 subjects who converted to sub clinical/overt hyperthyroidism in group B2, 47 (82%) had either anti TPO or anti Tg, 41 (72%) had anti TPO and 26 (46%) had anti Tg early. Between the subjects who converted to sub clinical/overt hypothyroidism and hyperthyroidism, there were no significant difference in subjects who were assessed for anti TPO alone compared to anti TPO or anti Tg together. But when assessed for anti Tg, for the subjects who converted to sub clinical/overt hypothyroidism (p=0.01314) and hyperthyroidism (p=0.0001) showed a significant difference compared to the combined anti TPO or anti Tg assessment. Hence, it clearly proved that there was no significant effect from anti Tg to the anti TPO performance, thus can be used as a standalone marker. But when the positivity of anti Tg was assessed alone and compared to the combined anti TPO or anti Tg assessment, the combined group of anti TPO or anti Tg showed significantly higher results than anti Tg alone.CONCLUSIONour results showed that thyroid autoantibodies have a strong early appearance in subjects who developed into sub-clinical/overt hypothyroidism and hyperthyroidism that has the likelihood of eventually developing in to clinical thyroid disease. Hence, it would be beneficial to use anti-TPO and anti-Tg as first line screening markers in conjunction with the primary thyroid markers, TSH and FT4 to plan frequent follow up testing to reduce long term morbidity and mortality. REFERENCES ADDIN EN.REFLIST 1.Ladenson, P. W.; Singer, P. A.; Ain, K. B.; Bagchi, N.; Bigos, S. T.; Levy, E. G.; Smith, S. A.; Daniels, G. H.; Cohen, H. D., American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000, 160 (11), 1573-5.2.Medici, M.; Korevaar, T. I.; Schalekamp-Timmermans, S.; Gaillard, R.; de Rijke, Y. B.; Visser, W. E.; Visser, W.; de Muinck Keizer-Schrama, S. M.; Hofman, A.; Hooijkaas, H.; Bongers-Schokking, J. J.; Tiemeier, H.; Jaddoe, V. W.; Visser, T. J.; Peeters, R. P.; Steegers, E. A., Maternal early-pregnancy thyroid function is associated with subsequent hypertensive disorders of pregnancy: the generation R study. J Clin Endocrinol Metab 2014, 99 (12), E2591-8.3.Triggiani, V.; Iacoviello, M., Thyroid disorders in chronic heart failure: from prognostic set-up to therapeutic management. Endocr Metab Immune Disord Drug Targets 2013, 13 (1), 22-37.4.Hampton, J., Thyroid gland disorder emergencies: thyroid storm and myxedema coma. AACN Adv Crit Care 2013, 24 (3), 325-32.5.Stockigt, J., Assessment of thyroid function: towards an integrated laboratory--clinical approach. Clin Biochem Rev 2003, 24 (4), 109-22.6.LeFevre, M. L.; Force, U. S. P. S. T., Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015, 162 (9), 641-50.7.Siemens Medical Solutions USA, I.8.Hutfless, S.; Matos, P.; Talor, M. V.; Caturegli, P.; Rose, N. R., Significance of Prediagnostic Thyroid Antibodies in Women with Autoimmune Thyroid Disease. J Clin Endocrinol Metab 2011, 96 (9), E1466–E1471. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download